- Open Access
Clinical significance of peripheral circulating tumor cell counts in colorectal polyps and non-metastatic colorectal cancer
© The Author(s). 2018
- Received: 18 September 2017
- Accepted: 26 December 2017
- Published: 22 January 2018
The presence of peripheral circulating tumor cells indicates the possible existence of a tumor in vivo; however, low numbers of circulating tumor cells (CTCs) can be detected in peripheral blood of healthy individuals as well as patients with benign tumors. It is not known whether peripheral CTC counts differ between patients with benign colorectal disease and those with colorectal cancer.
Comparative analysis of preoperative peripheral circulating tumor cells counts was completed in patients with benign colorectal disease (colorectal polyps) and non-metastatic cancer of the colon and rectum.
The results of this analysis showed that patients with colorectal cancer had higher CTC counts than patients with colorectal polyps (3.47 ± 0.32/3.2 ml vs 1.49 ± 0.2/3.2 ml, P < 0.001). Colorectal cancer patients with tumors of the sigmoid colon displayed the highest CTC counts (4.87 ± 0.95/3.2 ml), followed by those with tumors of the rectum (3.73 ± 0.54/3.2 ml), ascending colon (3.5 ± 0.63/3.2 ml), transverse colon (2.4 ± 0.68/3.2 ml), and descending colon (2.08 ± 0.46/3.2 ml). Colorectal polyp patients with polyps in the rectum showed the highest CTC counts (2.2 ± 0.77/3.2 ml), followed by those with polyps in the ascending colon (1.82 ± 0.54/3.2 ml), sigmoid colon (1.38 ± 0.25/3.2 ml), transverse colon (0.75 ± 0.25/3.2 ml), and descending colon (0.33 ± 0.21/3.2 ml). The differences in CTC counts suggest that anatomical location of colorectal tumors may affect blood vessel metastasis. Meanwhile, patients with moderately differentiated and poorly differentiated tumors displayed higher peripheral blood CTC counts compared to those with well-differentiated tumors (P < 0.001). This result suggests that the type of tissue differentiation of colorectal tumors may act as another factor that affects blood vessel metastasis.
Circulating tumor cells can be detected in the peripheral blood of colorectal cancer patients as well as patients with colorectal polyps. The differences in CTC counts suggest that anatomical location and the type of tissue differentiation of colorectal tumors may affect blood vessel metastasis.
- Circulating tumor cells
- Colorectal polyps
- Colorectal cancer
- Pathology types
Colorectal cancer is the most common cancer in the world [1–3], and radical surgery is the preferred treatment for patients with resectable colorectal tumors. Based on clinical pathological staging of tumors, integrated therapies can be performed subsequently, but many patients still exhibit asymptomatic tumor recurrence and metastasis within 5 years following surgery . Peripheral blood circulating tumor cells (CTCs) can be detected at the time of surgery in many patients, and thus, the presence of CTCs may indicate the potential for tumor recurrence and metastasis [4–6].
The presence of peripheral CTCs suggests that a tumor may be present in vivo, and preoperative detection of peripheral blood CTCs can be used to assess blood vessel metastasis of a tumor [7–9]. When combined with postoperative clinical and pathologic staging of the tumor, surgeons can comprehensively assess the need for subsequent treatments such as chemotherapy and radiation.
However, a low number of CTCs can be detected in the peripheral blood of some healthy individuals as well as patients with benign tumors [10, 11]. Therefore, further studies are required to determine whether peripheral CTCs are differentially expressed in benign colorectal disease and non-metastatic colorectal cancer and whether detection of CTCs accurately reflects the pathological characteristics of the primary tumor in benign and malignant colorectal diseases. To address these questions, we completed a comparative analysis of peripheral CTC counts in patients with colorectal polyps and colorectal cancer.
Characteristics of patients with polyps or carcinoma
Colonic and rectal polyps
Colonic and rectal carcinoma
P > 0.05
65.83 ± 1.10 (42–81)
68.86 ± 1.12 (36–87)
P > 0.05
CTC counts(n/3.2 ml)
1.49 ± 0.20 (0–4)
3.47 ± 0.32 (0–15)
P < 0.001
Tissue differentiation, n
Tissue pathology, n
Papillary tubular adenocarcinoma
Signet-ring cell carcinoma
Materials and chemicals
Cytokeratin (Pan, clone lineAE1/AE3), Cytokeratin 7 (clone line OV-TL 12/30), and Cytokeratin 20 (clone line SD33) mouse anti-human cell keratin monoclonal primary antibodies, as well as carcinoembryonic antigen (clone line COL-1) mouse anti-human carcinoembryonic antigen monoclonal primary antibody, were obtained from Biocare Medical (Walnut Creek, CA, USA). Horseradish peroxidase-conjugated second antibody (goat anti-mouse) was obtained from Jackson Immuno Research Inc. (West Grove, PA, USA). LCD45-AF594 fluorescent antibody was obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Nuclear staining (DAPI) antibody was obtained from Beyotime Biotechnology (Shanghai, China).
Circulating tumor cells
CTCs were enriched by negative separation. Briefly, CD45 antibody beads were used to bind white blood cells, and CTCs were enriched in precipitation. This method enriches for all CTCs, including epithelial cell adhesion molecule (EpCAM) negative, cytokine (CK) negative, and epithelial-mesenchymal transition (EMT) condition CTCs . A total of 9.6 ml of blood was obtained peripherally from each patient, across three collections (3.2 ml per collection) at three time points (8 a.m., 2 p.m., and 8 p.m.), using an indwelling sheathe syringe needle on the day before operation. Peripheral blood CTC counts were measured for each 3.2 ml blood sample using fluorescence in situ hybridization, which has been routinely applied in the clinic with high stability, sensitivity, and specificity. Peripheral blood CTC counts were repeated three times, and mean values were obtained. The following criteria were used to identify CTCs: nuclear signal greater than or equal to the triploid, positive nuclear DAPI staining, and negative CD45 staining. The following criteria were used to identify white blood cells: diploid nuclear signal, positive nuclear DAPI staining, and positive CD45 staining. Staining of cells was observed and counted using a fluorescence microscope (Nikon CI-S, Tokyo, Japan).
After surgeries and endoscopic resections, tumor tissues and polyp samples were immediately fixed in formalin for 24 hand paraffin embedded. Tissue sections were flattened on glass slides coated with poly-L-lysine. Sections were dewaxed in dimethyl benzene (30 min × 2), rehydrated in gradient alcohol (15 min intervals), washed in 1× phosphate buffer saline (PBS) (5 min × 3), and then incubated in 3% H2O2 for 10 min at room temperature to eliminate endogenous peroxidase activity. Sections were washed with 1× PBS (5 min × 3), and then incubated with 10% fetal bovine serum for 30 min. Primary antibodies (mouse anti human, 1:200) were added and incubated at 4 °C for one night. Sections were washed with 1× PBS (5 min × 3), and HRP-labeled secondary antibodies (goat anti mouse, 1:500) were added and incubated for 1 h. Sections were washed with 1× PBS (5 min × 3) and stained with diaminobenzidine for 15 min for color-developing. Sections were dyed with hematoxylin for 15 s, dehydrated in gradient alcohol at 15 min intervals, and incubated in xylene (30 min × 2). Sections were sealed with neutral resin and pictures were taken using a microscope.
Values are expressed as the mean ± standard error of the mean. Data were analyzed with Origin 8.0 software (OriginLab Corporation). Data recordings were evaluated by two-sample t test. P < 0.05 was considered as a statistically significant result.
Patient data and tumor characteristics
Characteristics of 61 patients with colonic or rectal polyps and 109 patients with colonic or rectal carcinoma were compared and analyzed (Table 1.). No significant difference was observed with respect to sex of the patients with colonic and rectal polyps or the patients with colonic and rectal carcinoma (X2 = 0.023, P > 0.05), and the ages of the patients with polyps or carcinoma were not significantly different (t = 1.829, P = 0.068). A significant difference was observed in peripheral CTC counts between patients with colonic and rectal polyps and patients with colonic and rectal carcinoma (t = 4.223, P < 0.001).
Tissue differentiation of colonic and rectal polyps was primarily classified as high-grade intraepithelial neoplasia (72.13%), whereas tissue differentiation of colonic and rectal carcinoma was mainly classified as moderately differentiated adenocarcinoma (69.72%). For tissue pathology, tubulovillous adenoma was the most common pathology in patients with colonic and rectal polyps (62.3%), whereas papillary tubular adenocarcinoma was the most common pathology in patients with colonic and rectal carcinoma (46.79%; Table 1).
Comparison of CTC counts between colorectal polyps and colorectal carcinoma
CTC counts in colorectal polyps and colorectal carcinoma
CTC counts (> 1/3.2 ml)
CTC counts (≤ 1/3.2 ml)
X 2 = 22.44
P < 0.001
Comparison of CTC counts in colorectal carcinoma at different anatomical locations
CTC counts and tissue differentiations at different anatomical locations of colorectal polyps and carcinoma
Anatomical locations of colorectal
Average CTC counts
3.73 ± 0.54
4.87 ± 0.95
2.08 ± 0.46
2.4 ± 0.68
3.5 ± 0.63
2.2 ± 0.77
1.38 ± 0.25
0.33 ± 0.21
0.75 ± 0.25
1.82 ± 0.38
Tissue differentiation, n
Relationship between CTC counts and tissue differentiation in colorectal polyps and colorectal carcinoma
CTC counts according to tissue differentiation in colorectal polyps
CTC counts (> 1/3.2 ml)
CTC counts (≤ 1/3.2 ml)
X 2 = 1.54
P > 0.05
CTC counts according to tissue differentiation in colorectal carcinoma
CTC counts (> 1/3.2 ml)
CTC counts (≤ 1/3.2 ml)
X2 = 23.39
*P < 0.001
X2 = 1.79
#P > 0.05
X2 = 21.85
△P < 0.001
The types of tissue differentiation of colorectal carcinoma at different anatomical locations were analyzed. In the sigmoid colon, where CTC counts (4.87 ± 0.95/3.2 ml) were the highest of all colorectal anatomical locations, moderate differentiation accounted for 73.91% (17/23), poor differentiation accounted for 17.39% (4/23), moderate and poor differentiation accounted for 91.3% (21/23), the combined percent of moderate and poor differentiation was the highest in all colorectal anatomical locations (Table 3), when compared to each other, no statistically significant difference were observed, although the ratio of moderately and poorly differentiated is highest in the sigmoid colon.
Relationship between CTC count and tissue pathology type
CTC counts according to tissue pathological types in colorectal polyps
CTC counts (> 1/3.2 ml)
CTC counts (≤ 1/3.2 ml)
X2 = 0.71
*P > 0.05
X2 = 0.25
#P > 0.05
X2 = 0.17
△P > 0.05
CTC counts according to tissue pathological types in colorectal carcinoma
CTC counts (> 1/3.2 ml)
CTC counts (≤ 1/3.2 ml)
X 2 = 0.76
*P > 0.05
X 2 = 0.39
#P > 0.05
X 2 = 0.72
#△P > 0.05
X 2 = 2.05
△P > 0.05
The importance of CTCs is becoming more apparent with recent advances in research [14–17]. Current research on CTCs involves RNA and DNA expression, cell signaling pathways, and circulating biomarkers in the blood [18–21]. Clinical detection of CTCs has been carried out in some medical institutions , but has been mainly applied as a tool for preliminary analysis and assessment of surgery and subsequent chemotherapy [15, 23–25]. There are limited clinical CTC studies available with large samples sizes. Although there are some studies on peripheral CTC counts in colorectal carcinoma [14, 17], few have analyzed CTC counts in patients with colorectal polyps and colorectal carcinoma, and these studies lack detailed comparative analysis in different parts of the colon and rectum. In this study, CTC counts and tumor pathological characteristics in patients with colorectal polyps or colorectal carcinoma were compared and analyzed. The results showed significantly higher peripheral CTC counts in patients with colonic and rectal carcinoma compared to patients with colonic and rectal polyps (P < 0.001).
Furthermore, CTC counts were noticeably different between patients with colorectal carcinoma and colorectal polyps with respect to anatomical location of the primary colorectal tumor. Specifically, CTC counts were significantly higher in colorectal carcinoma patients with tumors of the sigmoid colon (P < 0.001) and descending colon (P < 0.05) compared to colorectal polyp patients with tumors in the same location. This may result from differences in anatomy and tissue differentiation throughout the colon and rectum. Additionally, the duration of fecal retention was prolonged in the sigmoid colon, ascending colon, and rectum compared to other parts of the colon, and this was especially noticeable in patients who suffered from chronic constipation. It is possible that the prolonged duration of fecal retention resulted in stimulation of the intestinal wall, which could contribute to colonic mucosal disease [26–28]. The results also showed that tumors of the sigmoid colon were primarily moderately and poorly differentiated (combined total of 91.3% of tumors), no statistically significant difference were observed, although the ratio of moderately and poorly differentiated is highest in the sigmoid colon. Generally speaking, lower differentiated tumors had higher degrees of malignancy and more hematogenous metastasis. However, further clinical studies with large samples are required to validate this finding.
Previous studies have shown that low numbers of CTCs can be detected in the peripheral blood of some healthy individuals, as well as in patients with benign tumors [10, 11], suggesting that peripheral CTCs maybe detected in both benign and malignant colorectal disease. Indeed, CTCs were detected in patients with colorectal polyps in the present study. Furthermore, CTC counts were low or undetectable in some colorectal carcinoma patients in this study, and an overlap interval of CTC counts could be observed between patients with colorectal polyps and colorectal carcinoma. However, despite this overlap, there was a significant difference (P < 0.001) in CTC counts between patients with benign and malignant colorectal disease. When CTC counts were divided into two groups (> 1/3.2 and ≤ 1/3.2 ml), a significant difference was observed between colorectal polyps and carcinoma (P < 0.001). Specifically, higher CTC counts (> 1/3.2 ml) were observed in patients with colorectal carcinoma, whereas lower CTC counts (≤ 1/3.2 ml) were primarily observed in patients with colorectal polyps. However, when low numbers of CTCs are detectable, CTC counts cannot be used to indicate to the presence of benign or malignant colorectal disease due to the overlap in CTC counts between colorectal polyp patients and colorectal carcinoma patients. Based on the CTC counts in patients with different anatomical locations of colorectal polyps, CTC counts were highest in patients with rectal polyps (2.2 ± 0.77/3.2 ml). Therefore, the detection of peripheral CTCs could be used to indicate the presence of a malignant tumor in vivo, but only when counts are high (> 2.97/3.2 ml). Additionally, these findings confirm that peripheral CTCs can be detected not only in malignant tumors but also in benign disease, so if high peripheral CTCs detection value (> 2.97/3.2 ml) is used as a colorectal cancer screening criterion, some false positives will be eliminated as much as possible, and further research is required to determine the origin and significance of CTCs in patients with colorectal polyps.
There are very few studies assessing the application of peripheral CTC counts for determining the presence of a primary tumor and its pathological characteristics [17, 29]. One study showed that the median and overall survival of patients with peripheral blood circulating tumor cell counts ≥ 3/7.5 mL was shorter than that of patients with peripheral blood circulating tumor cell counts < 3/7.5 mL (P < 0.0001, ). This suggests that, if CTCs are uniformly distributed in the blood, a peripheral CTC count greater than 1/2.5 mL could indicate the presence of a primary tumor. Notably, this value is similar to the cutoff used in this study, where groups were divided into > 1/3.2 and ≤ 1/3.2 ml.
In order to identify the factors that influence the number of peripheral CTCs, the degree of tissue differentiation in colorectal polyps and colorectal cancer was analyzed. Colorectal polyps were classified as high-grade intraepithelial neoplasia (HGIEN) or low-grade intraepithelial neoplasia (LGIEN), where the former is considered as a precancerous lesion. Colorectal cancers were classified as highly differentiated, moderately differentiated, or poorly differentiated. In patients with colorectal polyps, the average CTC count was 1.49/3.2 ml. When CTC counts were divided into groups of > 1/3.2 and ≤ 1/3.2 ml, the degree of tissue differentiation in patients with colorectal polyps had no effect on peripheral blood CTC counts. The average CTC count in patients with colorectal cancer was 3.47/3.2 ml. When CTC counts were divided into two groups of > 1/3.2 and ≤ 1/3.2 ml, patients with moderately differentiated and poorly differentiated tumors displayed higher peripheral blood CTC counts compared to those with well-differentiated tumors. These results suggest that a lower degree of tissue differentiation in colorectal cancer tumors corresponds to higher peripheral CTC counts.
Tissue pathology in colorectal polyps and colorectal cancer was also analyzed as an additional factor that may influence peripheral CTC counts. Tissue pathologies of colorectal polyps were classified as serrated adenoma, tubular adenoma, tubulovillous adenoma, or proliferative polyps. Tissue pathologies of colorectal cancer were classified as papillary adenocarcinoma, tubular adenocarcinoma, papillary tubular adenocarcinoma, mucous adenocarcinoma, or signet-ring cell carcinoma. There was no difference between pathology types and CTC counts in colorectal polyps or colorectal carcinoma. Therefore, tissue pathology does not influence peripheral blood CTC count in colorectal disease.
In summary, peripheral blood CTCs can be detected in patients with colorectal cancer as well as in patients with colorectal polyps. A significant difference in peripheral CTC counts was observed between benign and malignant disease; patients with colorectal cancer had significantly higher CTC counts than patients with colorectal polyps. High CTC counts (> 2.97/3.2 ml) correlated with the presence of a primary tumor. CTC counts varied with respect to location of the primary tumor, indicating that anatomical location and degree of tissue differentiation may affect peripheral CTC counts. Additional clinical studies with larger sample sizes are required to further validate these findings.
The research funding on CTCs detection was obtained from patients’ medical insurance supported by the national health care costs. The design of the study and collection, analysis, and interpretation of data were performed by authors who contributed towards the article from the clinical data of patients; there is no specific fund support.
Availability of data and materials
Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.
We believe this work is scientifically valid, and all authors have sufficiently contributed to the study. CY conceived of the study, participated in its design and coordination, and helped to draft the manuscript. WZ and YH contributed to data collection. LZ conceived of the study, participated in its design, and helped to draft the manuscript. All authors read and approved the final manuscript.
Ethics approval and consent to participate
The study was carried on after acquiring patients’ consent and Tongren Hospital ethics committee approval and consent.
Consent for publication
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Cole SR, Tucker GR, Osborne JM, Byrne SE, Bampton PA, Fraser RJ, Young GP. Shift to earlier stage at diagnosis as a consequence of the National Bowel Cancer Screening Program. Med J Aust. 2013;198(6):327–30.View ArticlePubMedGoogle Scholar
- Siegel R, DeSantis C, Jemal A. Colorectal cancer statistics. CA Cancer J Clin. 2014;64:104–17.View ArticlePubMedGoogle Scholar
- Roder D, Karapetis CS, Wattchow D, Moore J, Singhal N, Joshi R, Keefe D, Fusco K, Powell K, Eckert M, Price TJ. Colorectal cancer treatment and survival: the experience of major public hospitals in South Australia over three decades. Asian Pac J Cancer Prev. 2015;16(6):2431–40.View ArticlePubMedGoogle Scholar
- Cohen SJ, Punt CJ, Iannotti N, et al. Relationship of circulating tumor cells to tumor response, progress ion-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26(19):3213–21.View ArticlePubMedGoogle Scholar
- de Bono JS, Scher HI, Montgomery RB, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2008;14(19):6302–9.View ArticlePubMedGoogle Scholar
- Cristofanilli M, Budd GT, Ellis MJ, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004;351(8):781–91.View ArticlePubMedGoogle Scholar
- Bork U, Grützmann R, Rahbari NN, Schölch S, Distler M, Reissfelder C, Koch M, Weitz J. Prognostic relevance of minimal residual disease in colorectal cancer. World J Gastroenterol. 2014;20(30):10296–304.View ArticlePubMedPubMed CentralGoogle Scholar
- Bork U, Rahbari NN, Schölch S, Reissfelder C, Kahlert C, Büchler MW, Weitz J, Koch M. Circulating tumour cells and outcome in non-metastatic colorectal cancer: a prospective study. Br J Cancer. 2015;112(8):1306–13.View ArticlePubMedPubMed CentralGoogle Scholar
- Souza E, Silva V, Chinen LT, Abdallah EA, Damascena A, Paludo J, Chojniak R, Dettino AL, de Mello CA, Alves VS, Fanelli MF. Early detection of poor outcome in patients with metastatic colorectal cancer: tumor kinetics evaluated by circulating tumor cells. Onco Targets Ther. 2016;9:7503–13.View ArticleGoogle Scholar
- Pantel K, Pantel K, Denève E, Nocca D, Coffy A, Vendrell JP, Maudelonde T, Riethdorf S, Alix-Panabières C. Circulating epithelial cells in patients with benign colon diseases. Clin Chem. 2012;58:936–40.View ArticlePubMedGoogle Scholar
- Tsai W-S, Chen J-S, Shao H-J, J-C W, Lai JM, Lu S-H, Hung T-F, Chiu Y-C, You J-F, Hsieh P-S, Yeh C-Y, Hung H-Y, Chiang S-F, Lin G-P, Tang R-P, Chang Y-C. Circulating tumor cell count correlates with colorectal neoplasm progression and is a prognostic marker for distant metastasis in non-metastatic patients. Sci Rep. 2016;6:24517.View ArticlePubMedPubMed CentralGoogle Scholar
- East JE, Atkin WS, Bateman AC, Clark SK, Dolwani S, Ket SN, Leedham SJ, Phull PS, Rutter MD, Shepherd NA, Tomlinson I, Rees CJ. British Society of Gastroenterology position statement on serrated polyps in the colon and rectum. Gut. 2017;66(7):1181–96.View ArticlePubMedPubMed CentralGoogle Scholar
- Gorges TM, Tinhofer I, Drosch M, Röse L, Zollner TM, Krahn T, von Ahsen O. Circulating tumour cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transition. BMC Cancer. 2012;12:178.View ArticlePubMedPubMed CentralGoogle Scholar
- Hardingham JE, Grover P, Winter M, Hewett PJ, Price TJ, Thierry B. Detection and clinical significance of circulating tumor cells in colorectal cancer-20 years of progress. Mol Med. 2015;21(Suppl 1):S25–31.View ArticlePubMedPubMed CentralGoogle Scholar
- Kasimir-Bauer S, Bittner AK, König L, Reiter K, Keller T, Kimmig R, Hoffmann O. Does primary neoadjuvant systemic therapy eradicate minimal residual disease? Analysis of disseminated and circulating tumor cells before and after therapy. Breast Cancer Res. 2016;18(1):20.View ArticlePubMedPubMed CentralGoogle Scholar
- Huang X, Gao P, Song Y, Sun J, Chen X, Zhao J, Liu J, Xu H, Wang Z. Relationship between circulating tumor cells and tumor response in colorectal cancer patients treated with chemotherapy: a meta-analysis. BMC Cancer. 2014;14:976.View ArticlePubMedPubMed CentralGoogle Scholar
- Mitra A, Mishra L, Li S. EMT, CTCs and CSCs in tumor relapse and drug- resistance. Oncotarget. 2015;6(13):10697–711.View ArticlePubMedPubMed CentralGoogle Scholar
- Gold B, Cankovic M, Furtado LV, Meier F, Gocke CD. Do circulating tumor cells, exosomes, and circulating tumor nucleic acids have clinical utility? A report of the Association for Molecular Pathology. J Mol Diagn. 2015;17(3):209–24.View ArticlePubMedPubMed CentralGoogle Scholar
- Strati A, Kasimir-Bauer S, Markou A, Parisi C, Lianidou ES. Comparison of three molecular assays for the detection and molecular characterization of circulating tumor cells in breast cancer. Breast Cancer Res. 2013;15:R20.View ArticlePubMedPubMed CentralGoogle Scholar
- Sawada T, Watanabe M, Fujimura Y, Yagishita S, Shimoyama T, Maeda Y, Kanda S, Yunokawa M, Tamura K, Tamura T, Minami H, Koh Y, Koizumi F. Sensitive cytometry based system for enumeration, capture and analysis of gene mutations of circulating tumor cells. Cancer Sci. 2016;107(3):307–14.View ArticlePubMedPubMed CentralGoogle Scholar
- El-Gayar D, El-Abd N, Hassan N, Ali R. Increased free circulating DNA integrity index as a serum biomarker in patients with colorectal carcinoma. Asian Pac J Cancer Prev. 2016;17(3):939–44.View ArticlePubMedGoogle Scholar
- Joosse SA, Gorges TM, Pantel K. Biology, detection, and clinical implications of circulating tumor cells. EMBO Mol Med. 2015;7(1):1–11.View ArticlePubMedGoogle Scholar
- Li TT, Liu H, Li FP, YF H, Mou TY, Lin T, Yu J, Zheng L, Li GX. Evaluation of epithelial-mesenchymal transitioned circulating tumor cells in patients with resectable gastric cancer: relevance to therapy response. World J Gastroenterol. 2015;21(47):13259–67.View ArticlePubMedPubMed CentralGoogle Scholar
- Rack B, Schindlbeck C, Jückstock J, Andergassen U, Hepp P, Zwingers T, Friedl TW, Lorenz R, Tesch H, Fasching PA, Fehm T, Schneeweiss A, Lichtenegger W, Beckmann MW, Friese K, Pantel K, Janni W, SUCCESS Study Group. Circulating tumor cells predict survival in early average-to-high risk breast cancer patients. J Natl Cancer Inst. 2014;106(5):dju066.View ArticlePubMedPubMed CentralGoogle Scholar
- Lu CY, Tsai HL, Uen YH, Hu HM, Chen CW, Cheng TL, Lin SR, Wang JY. Circulating tumor cells as a surrogate marker for determining clinical outcome to mFOLFOX chemotherapy in patients with stage III colon cancer. Br J Cancer. 2013;108(4):791–7.View ArticlePubMedPubMed CentralGoogle Scholar
- Parthasarathy G, Chen J, Chen X, et al. Relationship between microbiota of the colonic mucosa vs feces and symptoms, colonic transit, and methane production in female patients with chronic constipation. Gastroenterology. 2016;150(2):367–79.View ArticlePubMedGoogle Scholar
- Rubio CA, Puppa G, de Petris G, et al. The third pathway of colorectal carcinogenesis. J Clin Pathol. 2018;71(1):7–11. https://doi.org/10.1136/jclinpath-2017-204660. Epub 2017 Jul 27.
- Li S, Konstantinov SR, Smits R, et al. Bacterial biofilms in colorectal cancer initiation and progression. Trends Mol Med. 2017;23(1):18–30.View ArticlePubMedGoogle Scholar
- Paterlini-Brechot P, Benali NL. Circulating tumor cells (CTC) detection: clinical impact and future directions. Cancer Lett. 2007;253:180–204.View ArticlePubMedGoogle Scholar